VPS2.2 Antibody

What is VPS2.2 and how does it relate to CHMP2B?

VPS2.2 (Vacuolar protein sorting-associated protein 2-2) is an alternative name for CHMP2B (Charged multivesicular body protein 2b). This protein serves as a core component of the endosomal sorting required for transport complex III (ESCRT-III), which plays a critical role in multivesicular bodies (MVBs) formation and sorting of endosomal cargo proteins. The protein is also known by several other aliases including hVps2-2, CHMP2.5, Chromatin-modifying protein 2b, and CGI-84 . Understanding this nomenclature is essential when searching literature and antibody resources, as different research groups and commercial entities may use varied terminology.

What is the functional significance of VPS2.2/CHMP2B in cellular processes?

VPS2.2/CHMP2B functions primarily within the ESCRT-III complex, which is involved in membrane deformation and scission events. Specifically, this protein participates in:

• Formation of intraluminal vesicles (ILVs) within multivesicular bodies

• Sorting and degradation of membrane proteins (including growth factor receptors)

• Membrane fission events during cytokinesis

• Assisting in the budding of enveloped viruses (including HIV-1 and other lentiviruses)

• Mediating vesicle extrusion in conjunction with the AAA ATPase VPS4

These functions highlight VPS2.2/CHMP2B's critical involvement in membrane dynamics and protein trafficking, making it an important target for studies of cellular homeostasis and disease mechanisms.

How do I select the appropriate VPS2.2/CHMP2B antibody for my specific application?

Selecting the optimal VPS2.2/CHMP2B antibody requires careful consideration of several factors:

For VPS2.2/CHMP2B research, rabbit recombinant monoclonal antibodies have demonstrated high specificity and reproducibility across multiple applications . When selecting an antibody, prioritize those that have been validated using knockout cell lines, as this provides the strongest evidence for specificity .

What controls should I include when using VPS2.2/CHMP2B antibodies?

Implementing proper controls is essential for reliable interpretation of results:

• Negative controls:

  • CHMP2B knockout cell lines (such as the CHMP2B knockout U2OS cell line)

  • Primary antibody omission

  • Isotype controls (especially for flow cytometry)

• Positive controls:

  • Human placenta tissue lysates (known to express CHMP2B)

  • Neuronal cell lysates (brain tissue shows strong CHMP2B expression)

  • U2OS wild-type cells (osteosarcoma line with detectable CHMP2B)

• Loading/technical controls:

  • Housekeeping protein detection (e.g., GAPDH, β-actin)

  • Epitope-tagged CHMP2B constructs for overexpression studies

Implementing these controls ensures that any observed signal is specific to VPS2.2/CHMP2B rather than non-specific binding or technical artifacts.

What are the optimal conditions for Western blot detection of VPS2.2/CHMP2B?

Achieving clear, specific detection of VPS2.2/CHMP2B in Western blots requires careful optimization:

• Sample preparation:

  • Use RIPA buffer with protease inhibitors for efficient extraction

  • Heat samples at 95°C for 5 minutes in reducing conditions

  • Load 15-20 μg of total protein per lane

• Gel selection and transfer:

  • 10-12% polyacrylamide gels provide optimal resolution

  • PVDF membrane is preferred over nitrocellulose for CHMP2B detection

  • Semi-dry transfer at 15V for 60 minutes yields consistent results

• Antibody dilution and detection:

  • Primary antibody dilution: 1:1000 to 1:5000 depending on antibody source

  • Incubate overnight at 4°C for optimal binding

  • HRP-conjugated secondary antibodies at 1:5000 dilution

  • ECL detection with 5-6 minute exposure typically provides clear bands

• Expected results:

  • CHMP2B appears as a specific band at approximately 28-30 kDa

  • Potential post-translational modifications may result in additional bands

Remember that reducing conditions are essential for proper CHMP2B detection, as demonstrated in published protocols .

How can I optimize immunofluorescence staining for VPS2.2/CHMP2B in different cell types?

Successful immunofluorescence detection of VPS2.2/CHMP2B requires cell type-specific optimization:

• Fixation methods:

  • 4% paraformaldehyde (10 minutes) for most cell types

  • Methanol fixation (-20°C, 10 minutes) may better preserve certain ESCRT-III structures

• Permeabilization:

  • 0.1% Triton X-100 (5 minutes) for general applications

  • 0.05% saponin for better preservation of endosomal structures

• Blocking and antibody conditions:

  • 5% BSA or 10% normal serum (1 hour)

  • Primary antibody dilution: 1:100 to 1:500

  • Incubation overnight at 4°C for optimal specificity

• Cell type-specific considerations:

  • Neuronal cells: Require gentler permeabilization (0.05% Triton X-100)

  • Dividing cells: May show concentrated CHMP2B signal at midbody during cytokinesis

  • Endosomal studies: Co-staining with Rab7 or LAMP1 helps identify late endosomal/lysosomal localization

• Counterstaining recommendations:

  • DAPI for nuclear visualization

  • Phalloidin for actin cytoskeleton context

  • Early/late endosomal markers for compartment identification

When analyzing results, expect punctate cytoplasmic staining with potential enrichment in endosomal structures, consistent with CHMP2B's role in ESCRT-III function .

How can I use VPS2.2/CHMP2B antibodies to study the ESCRT machinery in virus budding?

Investigating ESCRT machinery involvement in viral budding requires specialized approaches:

• Dual immunofluorescence analysis:

  • Co-stain for CHMP2B and viral structural proteins

  • Analyze colocalization at plasma membrane budding sites

  • Conduct time-course experiments to capture dynamic recruitment

• Proximity ligation assays (PLA):

  • Use VPS2.2/CHMP2B antibody alongside antibodies against viral proteins

  • Detect direct protein-protein interactions at budding sites

  • Quantify PLA signal intensity as a measure of recruitment efficiency

• Immuno-electron microscopy:

  • Use gold-conjugated secondary antibodies against CHMP2B primary antibody

  • Visualize precise localization at neck of budding virions

  • Correlate with different stages of viral assembly and release

• Live-cell imaging approaches:

  • Combine antibody-based detection with live virus tracking

  • Use Fab fragments of anti-CHMP2B for live imaging

  • Monitor recruitment kinetics during viral egress

This multi-technique approach provides comprehensive insights into how VPS2.2/CHMP2B functions during viral budding, particularly for enveloped viruses like HIV-1 where ESCRT machinery plays a critical role .

What methods can I use to study VPS2.2/CHMP2B in neurodegenerative disease models?

VPS2.2/CHMP2B has been implicated in neurodegenerative conditions, particularly frontotemporal dementia. Research approaches include:

• Tissue analysis from disease models:

  • Immunohistochemistry in paraffin-embedded brain sections (use heat-induced epitope retrieval)

  • Western blot analysis of brain region-specific lysates

  • Compare expression patterns between affected and unaffected regions

• Co-localization with disease markers:

  • Double immunofluorescence with tau, TDP-43, or Aβ antibodies

  • Assess CHMP2B distribution in relation to protein aggregates

  • Quantify changes in endosomal morphology using CHMP2B as a marker

• Functional studies in neuronal models:

  • Primary neuron cultures from disease models stained for CHMP2B

  • Assessment of dendritic spine morphology in relation to CHMP2B distribution

  • Investigation of CHMP2B's role in presenilin-mediated Aβ production in endolysosomal compartments

• Patient-derived models:

  • iPSC-derived neurons from patients with CHMP2B mutations

  • Organoid models to study CHMP2B in 3D neural tissue context

  • Live imaging of endosomal trafficking using CHMP2B antibodies

These approaches reveal how alterations in VPS2.2/CHMP2B may contribute to disease pathogenesis, particularly through disruption of endolysosomal function in neurons .

How can I address non-specific binding when using VPS2.2/CHMP2B antibodies?

Non-specific binding is a common challenge that can be addressed through systematic optimization:

• For Western blotting:

  • Increase blocking time (2-3 hours) and concentration (5% BSA)

  • Use transfer buffer containing 20% methanol to reduce hydrophobic interactions

  • Test multiple antibody dilutions (1:1000, 1:2000, 1:5000)

  • Implement knockout controls to confirm band specificity

  • Increase washing duration and frequency (5 washes, 5 minutes each)

• For immunofluorescence:

  • Pre-adsorb antibody with cell/tissue lysate from knockout samples

  • Implement peptide competition assays to confirm epitope specificity

  • Use Sudan Black B (0.1%) to reduce autofluorescence in tissue sections

  • Optimize detergent concentration in wash buffers (0.05-0.1% Tween-20)

• For all applications:

  • Compare multiple CHMP2B/VPS2.2 antibodies targeting different epitopes

  • Consider recombinant monoclonal antibodies for highest specificity

  • Use fresh samples and avoid repeated freeze-thaw cycles

When troubleshooting, methodically change one parameter at a time while keeping detailed records of optimization steps and outcomes.

What strategies can address inconsistent VPS2.2/CHMP2B detection in different experimental conditions?

Inconsistent detection may stem from multiple factors that can be systematically addressed:

• Sample preparation variables:

  • Standardize lysis buffer composition (RIPA with 1% NP-40, 0.5% sodium deoxycholate)

  • Implement consistent sample handling (maintain samples on ice, avoid repeated freeze-thaw)

  • For tissue samples, optimize homogenization methods for specific tissue types

• Antibody-specific considerations:

  • Some antibodies may preferentially recognize specific post-translational modifications

  • Certain fixation methods may mask epitopes (compare PFA vs. methanol fixation)

  • Storage conditions affect antibody performance (aliquot and store at -20°C)

• Cell type and condition variables:

  • CHMP2B expression and localization changes during cell cycle

  • Stress conditions alter ESCRT complex assembly and distribution

  • Cell confluence affects endosomal trafficking and CHMP2B dynamics

• Technical approaches to improve consistency:

  • Use internal reference control (loading control) for normalization

  • Include positive control samples in each experiment

  • Standardize image acquisition settings for fluorescence microscopy

  • Implement automated analysis pipelines to reduce subjective interpretation

By systematically evaluating these factors, researchers can identify the source of variability and establish protocols that yield consistent, reproducible results.

How can VPS2.2/CHMP2B antibodies be utilized in studying endolysosomal dysfunction in neurodegeneration?

Recent research has highlighted the connection between endolysosomal systems, ESCRT machinery, and neurodegenerative processes:

• Analytical approaches:

  • Super-resolution microscopy with CHMP2B antibodies to examine endosomal morphology changes

  • Co-immunoprecipitation of CHMP2B to identify altered protein interactions in disease states

  • Quantitative analysis of CHMP2B distribution in relation to presenilin-containing endolysosomes

• Disease-relevant applications:

  • Investigation of CHMP2B's role in intraneuronal Aβ production within late endosomes

  • Analysis of CHMP2B recruitment to autophagosomes in neurodegenerative conditions

  • Examination of how CHMP2B mutations affect presenilin 2 function in endolysosomal compartments

• Methodological considerations:

  • Use of brain region-specific analysis in neurodegenerative disease models

  • Implementation of microfluidic chambers to study axonal vs. somatic endolysosomal dynamics

  • Combining CHMP2B immunostaining with live probes for endolysosomal pH or activity

This research direction is particularly promising given recent findings about presenilin 2's role in endolysosomal compartments and its connection to intraneuronal Aβ production .

What are the current methodological advances in studying VPS2.2/CHMP2B dynamics in live cells?

Traditional antibody approaches have limitations for live-cell studies, but several innovative techniques now enable dynamic analysis:

• Antibody fragment approaches:

  • Fab or scFv fragments derived from CHMP2B antibodies

  • Fluorescently labeled nanobodies against CHMP2B epitopes

  • Cell-permeable antibody-based probes for intracellular targeting

• Complementary genetic approaches:

  • CRISPR-Cas9 tagging of endogenous CHMP2B with fluorescent proteins

  • Split-GFP systems to detect CHMP2B interactions with binding partners

  • Photoactivatable or photoswitchable tags for pulse-chase dynamics

• Advanced imaging techniques:

  • Lattice light-sheet microscopy for high-speed, low-phototoxicity imaging

  • FRAP (Fluorescence Recovery After Photobleaching) to measure CHMP2B turnover rates

  • Single-molecule tracking to analyze CHMP2B recruitment to endosomes

• Quantitative analysis approaches:

  • Automated tracking of CHMP2B-positive vesicles

  • Intensity-based measurement of assembly/disassembly kinetics

  • Spatial statistics to quantify clustering and dispersal patterns

These emerging techniques allow researchers to move beyond static snapshots of CHMP2B localization to understand the dynamic behavior of this protein in living systems, providing crucial insights into its functional roles in health and disease.